5:27 PM
 | 
Oct 02, 2012
 |  BC Extra  |  Company News

Merck Serono spins out newco to develop AD assets

The Merck Serono S.A. division of Merck KGaA (Xetra:MRK) launched Asceneuron (Geneva, Switzerland) to develop the division's preclinical Alzheimer's disease programs targeting microtubule-associated protein-tau (MAPT; TAU, FTDP-17) and beta amyloid. Asceneuron will develop...

Read the full 162 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >